Saltar al contenido
Salud cardiovascularEnsayo aleatorizado6 min read

Evolocumab added to statins lowered LDL by 59% and reduced cardiovascular events

Colectivo editorial MoveVitals · Study published · Reading updated

Original paper:Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease · The New England Journal of Medicine · 2017 · Artículo original ↗

Idea principal

In 27,564 people with atherosclerotic cardiovascular disease already on a statin, adding evolocumab lowered LDL cholesterol by 59% versus placebo at 48 weeks and reduced the primary composite of cardiovascular events to 9.8% from 11.3% over a median 2.2 years (HR 0.85, 95% CI 0.79 to 0.92). Amgen funded the trial, follow-up was short, and only people with established disease took part, so the result does not speak to healthy people or to long-term safety.

Study design

Ensayo aleatorizado

Reading basis

Published abstract

Reading focus

Comparator & uncertainty

Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.

Pregunta de investigación

Evolocumab is a monoclonal antibody that inhibits a protein called PCSK9 (proprotein convertase subtilisin-kexin type 9), and the abstract's background says it lowers low-density lipoprotein (LDL) cholesterol by approximately 60%. Whether that translates into fewer cardiovascular events was uncertain. The trial enrolled patients with atherosclerotic cardiovascular disease who were already on statin therapy but whose LDL cholesterol was still 70 mg/dL or higher, and tested whether adding evolocumab lowers the risk of a composite of cardiovascular death, heart attack, stroke, hospitalization for unstable angina and coronary revascularization. The authors' conclusion also addresses whether lowering LDL cholesterol below current targets helps.

Población y método

FOURIER was a randomized, double-blind, placebo-controlled trial of 27,564 patients with atherosclerotic cardiovascular disease who were receiving statin therapy and had LDL cholesterol of 70 mg/dL (1.8 mmol/L) or higher. Patients were randomly assigned to evolocumab, given either as 140 mg every 2 weeks or as 420 mg monthly, or to matching placebo, all as subcutaneous injections, so neither patients nor investigators knew who received the drug. The abstract does not report participants' age, sex or countries, and full details are not in the abstract.

The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary end point was the narrower composite of cardiovascular death, myocardial infarction, or stroke. Median follow-up was 2.2 years. LDL cholesterol was compared at 48 weeks as the least-squares mean percentage reduction with evolocumab relative to placebo. The two composites are reported as numbers of patients and hazard ratios with 95% confidence intervals, and the abstract also describes subgroup results, including the quarter of patients with the lowest baseline LDL cholesterol, and a comparison of adverse events between the groups. It does not describe the statistical model.

Resultados

  1. 1
    Evolocumab lowered LDL cholesterol by a large margin: at 48 weeks the least-squares mean reduction versus placebo was 59%, from a median baseline of 92 mg/dL (2.4 mmol/L) to 30 mg/dL (0.78 mmol/L) (P<0.001).
  2. 2
    Fewer patients had a primary composite event with evolocumab: 1344 patients (9.8%) versus 1563 patients (11.3%) with placebo, a hazard ratio of 0.85 (95% CI 0.79 to 0.92; P<0.001). The hazard ratio is a relative measure; the absolute difference is the gap between those two percentages over a median 2.2 years.
  3. 3
    The narrower key secondary composite of cardiovascular death, myocardial infarction or stroke was reduced by a larger relative amount: 816 patients (5.9%) versus 1013 patients (7.4%), a hazard ratio of 0.80 (95% CI 0.73 to 0.88; P<0.001).
  4. 4
    The results were consistent across key subgroups, including patients in the lowest quartile for baseline LDL cholesterol (median 74 mg/dL, or 1.9 mmol/L), so the benefit was not confined to people who started with the highest levels.
  5. 5
    Adverse events did not differ significantly between the groups, including new-onset diabetes and neurocognitive events, with one exception: injection-site reactions were more common with evolocumab (2.1% versus 1.6%).
  6. 6
    The authors conclude that patients with atherosclerotic cardiovascular disease benefit from lowering LDL cholesterol below current targets, drawing on the achieved median of 30 mg/dL; that is an inference beyond the drug-versus-placebo comparison itself.

Límites e incertidumbre

  1. 1
    The abstract states no limitations of its own. Our observation: median follow-up was 2.2 years, so the abstract says nothing about benefit or harm beyond that window, and the finding of no significant difference in adverse events cannot rule out problems that appear later or are rare.
  2. 2
    Our observation: the trial enrolled only people with established atherosclerotic cardiovascular disease who were already on a statin and had LDL cholesterol of 70 mg/dL or higher, so it does not apply to primary prevention or to people with lower LDL cholesterol.
  3. 3
    Our observation: patients were randomized to a drug, not to LDL cholesterol levels, so the conclusion about benefit below current targets is an inference from the achieved median of 30 mg/dL, and the abstract gives no estimates for the individual subgroups.
  4. 4
    Our observation: the relative reductions (hazard ratios 0.85 and 0.80) translate into smaller absolute differences (9.8% versus 11.3%, and 5.9% versus 7.4%), which matters when weighing the benefit against injections, cost and side effects.
  5. 5
    Amgen funded the trial, as the abstract discloses; the sponsor's role in design and analysis is not described there. This reading rests on the abstract alone.

Relevancia práctica

For people who already have atherosclerotic cardiovascular disease and take a statin, this trial shows that lowering LDL cholesterol much further, with a drug that cut it by 59%, reduced the risk of cardiovascular events (hazard ratio 0.85), and the relative effect was similar in the subgroup that started lowest. If your own LDL cholesterol stays at or above 70 mg/dL on a statin, that is a reason to ask your cardiologist or physician what options exist; the trial shows an average effect, not that the drug suits any one person.

It is not a reason to start, stop or change any medicine on your own, it does not show benefit for people without established disease, and the absolute gaps over about 2 years were 9.8% versus 11.3% for the main composite. Injection-site reactions were more common with the drug. Confidence in the benefit is high for this population because it was a large randomized double-blind trial; confidence about long-term effects is lower because follow-up was a median 2.2 years.

Tus datos

Wearables do not measure LDL cholesterol, so this is a blood-test topic, not a watch topic. Keep the date, units (mg/dL or mmol/L), fasting status and current medicines of each lipid panel together, and compare results from the same lab over months rather than reacting to one value. Heart rate, HRV, step or sleep trends cannot show whether an LDL-lowering treatment is working or whether plaque is changing.

Cómo interpretar la evidencia

Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.

Fuentes y atribución

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

The New England Journal of Medicine · 2017-05-04

DOI: 10.1056/NEJMoa1615664 ↗PubMed · 28304224 ↗

Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada

Fuentes verificadas 2026-11-01

Guías prácticas

Leer en contexto

·Metaanálisis observacional

Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people

Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.

Journal of the American Heart Association

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Five exercise types lowered resting blood pressure, isometric training the most

Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Ensayo aleatorizado

A salt substitute lowered stroke, major cardiovascular events and death in rural China

In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.

The New England Journal of Medicine

Explicaciones detalladasLeer estudio →
·Estudio/revisión de validación

Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation

Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.

The New England Journal of Medicine

Explicaciones detalladasLeer estudio →
Salud cardiovascular →